No Long Term Benefit to Adjuvant Metformin in Type 1 Diabetes

http://type2diabetestreatment.net/diabetes-type-1/no-long-term-benefit-to-adjuvant-metformin-in-type-1-diabetes/
Brian Ellis April 05, 2017 No Long Term Benefit to Adjuvant Metformin in Type 1 Diabetes Share this content:

• facebook
• twitter
• linkedin
• google

Adjuvant therapy with metformin did not provide long-term benefits to patients with type 1 diabetes.

Despite providing small short-term decreases in body mass index (BMI) and insulin dose, metformin as an adjunct to intensive insulin therapy failed to produce long-term benefits in patients with type 1 diabetes, concluded recent findings.

The 10-year retrospective study included 2 cohorts with type 1 diabetes: group 1 received adjuvant metformin for ≥6 months (n=186), and group 2 either refused metformin (n=25) or adhered to the therapy <6 months (n=37). The 2 cohorts had their BMIs, hemoglobin A1c (HbA1c) levels, and daily insulin doses registered on an annual basis.

Continue Reading Below

As a reference for baseline comparison, researchers used a third cross-sectional group of 961 patients with type 1 diabetes who were not offered adjuvant metformin.

Baseline data indicated that BMI was significantly higher and insulin dose lower for patients in group 1; HbA1c levels did not significantly differ.

During the first years of metformin therapy, patients in group 1 experienced a small but nonsignificant decrease in BMI and insulin dose. However, by year 10, no effects were reported in BMI, insulin dose, or HbA1c levels.

According to researchers, study limitations included the heterogeneousness of groups 1 and 2 at start; the lack of registration during follow-up concerning concomitant medication use, intercurrent disease, sports activity, or dietician contact; and the absence of hard end point evaluation.

"We conclude that metformin is not associated with long-term beneficial effects on BMI, HbA1C, or daily insulin disease when added as adjunct therapy to intensive insulin therapy in patients [with type 1 diabetes]," the researchers wrote.

Related Articles

• Glycemic Control Not Improved By Metreleptin in Suboptimally Controlled Type 1 Diabetes
• Acute Kidney Injury Rate High in Hospitalized Children With Diabetic Ketoacidosis
• Complication Rates In Adolescents With Type 1 vs Type 2 Diabetes

Reference

Staels F, Moyson C, Mathieu C. Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus [published online March 20, 2017]. Diabetes Obes Metab. doi:10.1111/dom.12948

Related Topics

• Type 1 Diabetes

Endocrinology Advisor Articles

• Revisiting the Legality of Curbside Consults in Clinical Practice
• Long-Term Androgen Therapy Increases Cardiovascular Risk in Transgender Men
• Systemic Anti-inflammatory Effects of Linagliptin in Type 2 Diabetes
• Empagliflozin Use Supported in Patients With DM Post-Cardiac Transplantation
• Does Metformin Therapy During Pregnancy Affect Metabolic Health in PCOS?

• Do Gluten-Free Diets Elevate Type 2 Diabetes Risk?
• Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in Type 2 Diabetes
• Limited Association Between Depression and Vitamin D Deficiency
• Is Diabetes a Modifier of CV Risk After DAPT Cessation Post-DES PCI?
• Revisiting the Legality of Curbside Consults in Clinical Practice

• Recommended Dietary Allowance of Vitamin D3 Lower Than IOM Suggestion
• Significant Fracture Burden, Psychological Comorbidities Associated With Hypophosphatasia
• Circadian Preference Linked to Depression Rates in Type 2 Diabetes
• Does Metformin Therapy During Pregnancy Affect Metabolic Health in PCOS?
• Elevated Pancreatic Polypeptide May Predict Coronary Artery Disease in T2DM

Sign Up for Free e-Newsletters

Pre Diabetes Treatment
Vegerarian Diabetic Diet
Diabetes Free Review
Original Article
#Diabetes_Type_1
#obesity_help